molecular biology and immunology techniques along with multi-omics approaches, including sc-RNA-seq, bulk RNAseq, epigenomics, metabolomics, proteomics, CRISPR screens and genetically engineered mouse models and organoid models of pancreatic cancer.
The ideal candidate should possess a Ph.D or M.D./Ph.D in the field of Immunology/ Molecular Biology/ and Cancer Biology with expertise in flow cytometry, cell-based assays, and/or animal studies. For more detail, please refer to our recent articles (Cancer Discovery, 2024, Molecular Cancer, 2026, Nature Cell Biology, 2024, Oncogene. 2022, Trends Immunol. 2022, Gastroenterology 2021, JEM 2020). The Mehla Lab offers a friendly, supportive, and collaborative environment with great excitement for cancer research. Our future research objectives include, but are not limited to, cell-based therapeutics.
Interested candidates should submit their CV directly to Dr. Mehla at kamiya-mehla@ou.edu
The University, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, marital status, genetic information, gender identity/expression (consistent with applicable law), age (40 or older), religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes but is not limited to admissions, employment, housing, financial aid, and educational services.
